HUE029693T2 - Packaging assembly to prevent premature activation - Google Patents

Description

Description

BACKGROUND

[0001] The present disclosure relates generally to packaged medical device assemblies and more specifically to combinations of packages with medical devices.

[0002] Certain drugs are supplied in lyophilized form. The lyophilized drug must be mixed with water to reconstitute the drug into a form suitable for injection into a patient. In particular, the components that form the injectable solution must be sterile to avoid infection. The reconstitution process presents difficulties to patients or caregivers who need to inject themselves or another, for example, in a home environment. The patient or caregiver has to follow a sequential manipulation of the drug container, the diluent container and the transfer syringes, which use needles to penetrate the stoppers associated with the respective containers. The patient or caregiver needs to follow established aseptic practices to avoid contamination.

[0003] As described in U.S. Patent Application No. 13/217,967 ("the ’967 Application"), the drug container, the diluent container and the transfer syringes of the device are mounted within a same housing at time of shipping from the manufacturer, distributor or assembler to the end user. Due to the specific arrangement of the transfer syringes with respect to each of the drug containers, extra care is taken to prevent accidental premature puncture or activation of the stoppers of the containers by the transfer syringes during shipment and handling. Shipment of reconstitution devices accordingly presents challenges in preventing premature activation of the product, ensuring sterility and enabling ease of use of the product by the end user. The lyophilized drugs are often very expensive, making the minimization of accidental activation or contamination suffered during shipment even more important. EP 0 614 653 A2 discloses a fluid delivery system comprising a vial for containing a dry medicament, a container for holding a solution, pierceable plugs sealing the vial and the container, a capsule having upper and lowerends for receiving the container and the vial and a sliding member disposed in the capsule having upper and lower needles for piercing the plugs sealing the container and the vial.

SUMMARY

[0004] According to the present invention there is provided a medical package assembly according to claim 1, a drug delivery product according to claim 11 and a method of packaging a drug reconstitution assembly according to claim 19.

[0005] The present disclosure provides a packaged assembly including a package and a reconstitution assembly and associated medical products, which prevent premature activation of the reconstitution assembly. The package is shaped to cradle the reconstitution assembly. The package integrates with pertinent features of the reconstitution assembly, and maintains the isolation ofvar-ious parts of the reconstitution assembly from one another in the package during shipment and handling.

[0006] In one embodiment, the reconstitution assembly includes a housing having an upper sleeve and lower sleeve. The housing defines a generally tubular passageway and includes a plurality of radially spaced apertures in the upper sleeve, and a plurality of radially spaced windows in the lower sleeve. A transfer set assembly is disposed within the housing between the lower sleeve and the upper sleeve. The transfer set assembly includes a pair of opposing spikes including an upper spike and a lower spike. The upper and lower spikes form part of a flow path.

[0007] A first container is disposed at least partially inside the upper sleeve of the housing, within the passageway and neartheupperspike.Thefirst container includes a first vial and a first stopper providing a sterile barrier to the medicament contents held within the first vial. The first container is disposed in one embodiment so that the first stopper faces downward or towards a center of the housing. A second container is disposed inside the lower sleeve within the passageway near the lower spike. The second container includes a second vial and a second stopper providing a sterile barrier to the contents of the second vial. The second container is disposed in one embodiment so that the second stopper faces upward towards the first stopper. The flow path formed by the spike allows the containers when spiked to communicate fluidly with each other.

[0008] In an embodiment, the upper spike of the transfer set assembly pierces the first stopper upon application of a first force to the first container. The force can be from the patient or caregiver pressing down on the first container to push the first container into the housing and onto the upper spike. Subsequent to the upper spike piercing the first stopper of the first container, the second container is allowed to move axially relative to the transfer set assembly. The lower spike of the transfer set assembly then pierces the second stopper upon application of a second force and the engagement of a triggering mechanism by the first container, and specifically the first vial of the first container. When the second stopper is pierced, the vacuum of the second container is accessed. The first and second forces may be predetermined forces or at a desired level.

[0009] In an embodiment, the first container encloses a liquid and the second container encloses a lyophilized product. Piercing the first stopper of the first container with the upper spike, and piercing the second stopper of the second container with the lower spike places the first and second containers into fluid communication with each other through the flow path of the transfer set assembly. The vacuum of the second container then causes the liquid of the first container to aspirate through the fluid pathway into the second container. The liquid mixes with the lyophilized drug to formulate the drug for patient use.

[0010] The packaging assembly is constructed so that the reconstitution assembly fits within the package and the package physically inhibits axial translation of either thefirst container or the second containerwithin the housing. By inhibiting any significant axial translation of the first or second containers within the housing, accidental or premature piercing of either the first stopper of the first container by the upper spike or the second stopper of the second container by the lower spike is prevented.

[0011] In an embodiment, the package includes an interior chamber formed with a plurality of recesses and protrusions that are shaped to compliment mating features of the reconstitution assembly. The interior chamber of the package is formed such that the reconstitution assembly properly engages with the complimentary recesses and protrusions of the package in a predetermined configuration. For example, there are first and second recesses at the ends of the package that cradle the first and second vials of the first and second containers extending from the housing of the reconstitution assembly. A plurality of protrusions extending into the interior chamber of the package match with and extend through a plurality of apertures in the uppersleeve and a plurality of apertures in the lower sleeve of the reconstitution assembly housing.

[0012] The apertures in the housing allow the protrusions of the package body to extend into the passageway formed by the housing, and engage the vials around a portion of the neck of the vials, which can be small glass bottles with necked openings. The protrusions catch the housing apertures so as to prevent the first and second respective containers from rotating within the package. The engagement of the protrusions with the necks of the vials also prevents inadvertent axial translation of the containers relative to either one another, the transfer set assembly, or the housing. By keeping thefirst and second containers generally axially static relative to one another and relative to the transfer set assembly, the protrusions of the interior chamber of the package body maintain the upper spike and the lower spike at a separation distance from each of the first container and the second container respectively. Because the axial translation of the components of the reconstitution assembly during shipping or handling is minimized or prevented, the instances of premature puncture of the first or second containers by the respective spikes of the transfer set assembly is also minimized.

[0013] Additional features and advantages are described herein, and will be apparent from the following Detailed Description and the figures.

BRIEF DESCRIPTION OF THE FIGURES

[0014] FIG. 1 is a perspective view of one embodiment of an assembled package of the present disclosure. FIG. 2 is an exploded view of one embodiment of the package, a reconstitution assembly contained in the package and a cover for the package of the present disclosure. FIG. 3 is a body-side view of one embodiment of the assembled package and drug reconstitution assembly of the present disclosure. FIG. 4 is a sectioned view of the assembled package of FIG. 3 taken along line IV-IV of FIG. 3. FIG. 5 is a bottom view of one embodiment of the package of the present disclosure. FIG. 6 is a sectioned view of the package of FIG. 5 taken along line VI-VI of FIG. 5. FIG. 7 is a side elevation view of one embodiment of the assembled package of the present disclosure. FIG. 8 is an end elevation view of one embodiment of the assembled package of the present disclosure.

DETAILED DESCRIPTION

[0015] The present disclosure provides a packaged assembly including an assembled package and reconstitution assembly. The packaged assembly is especially useful for preventing premature activation of the reconstitution assembly during shipping and handling. Although the packaged assembly is described primarily herein as including a reconstitution assembly, it will be apparent that the an appropriately configured package may be used during shipment of other drug assemblies, or other products that have components separated prior to use.

[0016] Referring now to the drawings and in particular to FIGS. 1 and 2, an assembled package 10 is generally indicated. Assembled package 10 in general includes a removable lid 12, a body 14, and a drug reconstitution assembly 100 (FIG. 2).

[0017] Removable lid 12 can be made of any one or more of a high-density polyethylene fibers, such as TY-VEK®, a foil material or a paper material, and is adhered to the body 14 with heat activated adhesive in one embodiment. The adhesive and application process enables removable lid 12 to remain securely adhered to the body 14 but to also be relatively easily removed by the patient.

[0018] Body 14 can be constructed from a thermofor-mable polyethylene terephthalate ("PET") material. Body 14 can be formed into its desired shape with protrusions 16,18, wells 20a to 20c, etc., formed via a thermoforming process. In an alternative embodiment, body 14 is made of a polymeric material and is formed via an injection molding process.

[0019] As illustrated in FIGS. 1 and 2, lid 12 attaches sealingly and removably to body 14 to enclose the drug reconstitution assembly 100 within package 10. Removable lid 12 can provide a flat surface upon which manufacturer instructions and identifying information can be displayed. The information identifiers may include barcodes, picture codes, company information and internet addresses directing the user to more detailed information. The information may include medication information, patient identification and prescription information, manufacturer information, licensing and governmental agency information, creation and expiration date information, and directions for use.

[0020] As illustrated in FIGS. 1 and2, body 14isformed to define an interior chamber, which includes a plurality of protrusions 16 and 18 that protrude into the chamber and wells 20a to 20c that extend away from the interior of the chamber. These features are described in greater detail below. As used herein, protrusions in general extend in towards a center of the interior chamber of body 14, while wells in general extend out away from the center of the interior of the chamber.

[0021] The interior chamber accepts drug reconstitution assembly 100 as illustrated in FIG. 2. Drug reconstitution assembly 100 includes a housing 110 having an upper portion 112 (when held for use) and a lower portion 114 (when held for use). The upper portion 112 and lower portion 114 form a generally cylindrical passageway. The drug reconstitution assembly 100 also includes an upper container 120 (when held for use) housed at least partially within the passageway formed by the upper portion 112 of the housing, a lower container 130 (when held for use) housed at least partially within the passageway formed by a lower portion 114 of the housing, and an access port plug 140 provided on the outside of housing 110. Removable lid 12 of package 10 attaches sealingly to body 14 to enclose the drug reconstitution assembly 100 within the body 14.

[0022] Referring now to FIG. 3, a body side view of the assembled package 10 from the outside looking in is illustrated. A first pair of protrusions 16 and a second pair of protrusions 18 extend from the surrounding surface of body 14 into the interior chamber to contact mating features of drug reconstitution assembly 100. Wells 20a, 20b, and 20c extend outwardly from the interior chamber relative to surrounding surfaces of body 14. Wells 20a, 20b, and 20c are at least substantially flat and coplanar with each other (see also FIGS. 1 and 2), such that package 10 can be rested on the body side by setting wells 20a, 20b, and 20c onto a stable surface. Body 14 also forms wells 22 and 24 at the upper and lower ends of body 14 as illustrated in FIGS. 1 to 3.

[0023] Referring now to FIG. 4, a cross-sectional side view of FIG. 3 taken along the line IV-IV is illustrated. Due to the radial spacing and geometry of protrusions 16 compared to the radial spacing and geometry of protrusions 18, line IV-IV has been staggered in FIG. 3 to better show the cross-sections of both protrusions 16 and 18 in the single view of FIG. 4. The cross-section view of the reconstitution assembly 100 and its housing 110 illustrate the contents of the reconstitution assembly. Specifically, the reconstitution assembly 100 includes first or upper container 120, second or lower container 130, and a transfer set assembly 200.

[0024] As discussed in detail in the ’967 Application, transfer set assembly 200 includes an upper spike 202, a lower spike 204, and a flow path that travels through the upper spike 202 and the lower spike 204. Upper spike 202 faces an opening 128 of the upper container 120, while lower spike 204 faces an opening 138 of the lower container 130. In various embodiments, the plastic part of transfer set assembly 200 is made of a suitable mold-able and sterilizable plastic such as acrylonitrile butadiene styrene ("ABS"), polycarbonate ("PC") or acrylic.

[0025] Upper spike 202 can include an upper boot 206 configured to cover and maintain sterility of a lower portion of the upper spike and its flow path portion. Similarly, the lower spike 204 includes a lower boot 208 configured to cover and maintain sterility of an upper portion and the flow path in the lower spike. Upper 206 and lower 208 boots in one embodiment are made with an elastomeric material that is relatively easily punctured by the upper spike 202 and lower spike 204 respectively, upon activation of the drug reconstitution assembly 100.

[0026] Transfer set assembly 200 can also include a syringe port pathway (beneath plug 140 illustrated in Fig. 2) that is generally perpendicular to and maintains a valved fluid communication with the flow path traveling through the upper spike 202 and the lower spike 204. The syringe port pathway can alternatively extend non-perpendicularly from the flow path of the transfer set assembly 200. The syringe port pathway communicates with a syringe port extending through housing 110 of reconstitution assembly 100. In FIG. 2, a syringe port plug 140 engages the syringe port to maintain the sterility of the port and connecting flow paths.

[0027] Afterfull activation of the drug reconstitution assembly 100, a user removes the syringe port plug 140 to reveal the syringe port that the user can access via a separate syringe. Syringe port plug 140 is made of an elastomeric or a rubber material, such that it can be bent for grasping and removing. The syringe port pathway and spike flow paths allow fluid communication from the syringe port to the upper and lower containers 120 and 130.

[0028] U pper 120 and lower 130 containers include up-per121 and lower131 vials, which are made of a suitable medical grade, sterilizeable glass or plastic, for example. Upper vial 121 and lower vial 131 are each generally cylindrical and have similar geometries, including a neck portion 122a, 132a, a main portion 122c, 132c, and a rim portion 126, 136. The neck portion 122a, 132a has a smaller diameter than either the main portion 122c, 132c or the rim portion 126,136. Upperstopper 124 sealingly plugs the upper opening 128 of the upper vial 121 to prevent contamination or leakage of the contents of the upper container 120. Similarly, lower stopper 134 sealingly plugs the lower opening 138 of the lower vial 131 to prevent contamination or leakage of the lower container 130. Upper stopper 124 and the lower stopper 134 can be made of rubber or an elastomeric material. It should be appreciated that the assembly of the upper vial 121 and the upper stopper 124 is defined herein as the upper container 120. Similarly, the assembly of the lower viaM 31 and the lower stopper 134 is defined herein as the lower container 130.

[0029] Housing 110 of reconstitution assembly 100 includes an upper housing portion 112 and a lower housing portion 114, which again can be made of acrylonitrile butadiene styrene ("ABS"), polycarbonate ("PC") or acrylic. Upper housing portion 112 includes or defines a plurality of apertures 116, while lower housing portion 114 includes or defines a plurality of apertures 118 (illustrated best in FIG. 2). Apertures orwindows 116 and 118 are each spaced apart radially around the respective housings. Apertures 116, 118 allow for gas sterilization to flow to the internal parts and components of reconstitution assembly 100. In addition to easing the sterilization process, apertures 116, 118 provide at least partial access to the upper 120 and lower 130 containers when housed within reconstitution housing 110.

[0030] As is discussed in more detail in the ’967 Application, upon activation of the drug reconstitution assembly 110, the upper spike 202 penetrates the upper boot 206 and upper stopper 124 to access the contents of the upper container 120, afterwhich the Iowerspike204 penetrates the lower boot 208 and lower stopper 134 to access the contents of the lower container 130. A flow path is created between the upper container 120 and the lower container 130 when the upper 202 and lower spikes 204 have accessed the contents of the upper 120 and lower containers 130 respectively. The ’967 Application discusses other internal mechanisms of assembly 110 that ensure that upper container 120 travels towards the upper spike 202, and that the upper stopper 124 is fully penetrated by the upper spike 202 before lower spike 204 can contact the lower stopper 134 of the lower container 130.

[0031] FIG. 4 illustrates how containers 120 and 130 fit within housing 110 of the drug reconstitution assembly 100 and how the drug reconstitution assembly 100 fits within the interior chamber of package body 14 during shipment (unactivated state). As illustrated, upper container 120 fits at least partially within the upper housing portion 112. The upper rim 126 of upper vial 121 and upper stopper 124 are each oriented toward the transfer set assembly 200 and upper spike 202. In the illustrated unactivated state, upper stopper 124 of upper container 120 is disposed nearthe upper spike 202, but not in contact with the upper spike 202.

[0032] Upper housing portion 112 in one embodiment includes three apertures 116 substantially evenly radially disposed about the upper housing portion 112, as partially illustrated in FIG. 2. It should be appreciated that any number of apertures may be incorporated into the upper housing portion 112, and the spacing need not be equal or radial. Upper housing portion 112 is formed such that when upper container 120 is secured in its shipping configuration, various features of upper vial 121, such as the upper shoulder 122b, upper neck 122a, and upper rim 126, are aligned longitudinally with the apertures 116.

[0033] Similar to the upper container 120, the lower container 130 fits at least partially within the lower housing portion 114. Lower rim 138 of lower vial 131 and lower stopper 134 are each oriented towards lower spike 204 of the transfer set assembly 200. In the unactivated state (as illustrated), lower stopper 134 of the lower container 130 is disposed near the lower spike 204, but not in contact with the lower spike 204 of the transfer set assembly 200.

[0034] The lower housing portion 114 in one embodiment includes six apertures 118 evenly, radially disposed about the lower housing portion 114, as partially illustrated in FIG. 2. Any suitable number of apertures may be incorporated into the lower housing portion 114 and need not be the spaced evenly or radially. In FIG. 4 two of apertures 118 of lower housing portion 114 are visible. Lower housing portion 114 is formed such that when lower container 130 is secured in its shipping configuration, various features of lower vial 131, such as lower shoulder 132b, lower neck 132a, and the lower rim 136, are aligned longitudinally with apertures 118.

[0035] It is important that upper container 120 and the lower container 130 do not shift out of their shipping configuration before the user intentionally activates drug reconstitution assembly 100. Such an undesirable displacement of either the upper container 120 or the lower container 130, caused by shipment, handling, or mishandling, could result in premature contact between the upper 202 or lower 204 spikes and the respective upper 124 or lower 134 stoppers. Even rupture or disturbance of the relatively thin boots 206 and 208 by the respective spikes 202 and 204 can destroy the sterile environment of the flow path traveling through the spikes 202 and 204 of the transfer set assembly 200. Package 10 prevents these undesirable displacements as discussed in detail below.

[0036] It should be appreciated that, for the present disclosure, an undesirable displacement defines any one of a plurality of different resulting positions of the upper 120 and lower 130 containers, the upper 202 and lower 204 spikes, the upper 124 and lower 134 stoppers, the upper 206 and lower 208 boots, the transfer set assembly 200, and the housing 110. Each of the undesirable displacement positions that could occur unintentionally during shipping is prevented by the body 14’s interaction with the drug reconstitution assembly 100. Described below are several undesirable displacement positions. It should be appreciated that, although discussed with respect to both the upper and lower containers, it is contemplated that each of the undesirable displacement positions applies either individually or collectively to each of the upper 120 and lower 130 containers.

[0037] In a first undesirable displacement position, the upper container 120 or lower container 130 axially shifts relative to the transfer set assembly 200 such that the upper stopper 124 or lower stopper 134 makes contact with upper boot 206 or lower boot 208, which in turn makes contact with and is at least partially pierced by upper spike 202 or lowerspike 204, respectively. It should be appreciated that in the first undesirable displacement position, the respective spike 202,204 does not fully penetrate the upper 124 or lower 134 stopper. In the first undesirable displacement position, the puncture of the upper 206 and lower 208 boots by the respective upper 202 and lower 204 spikes makes the transfer set assembly 200 and its flowpath susceptible to contamination.

[0038] In a second undesirable displacement position, the upper container 120 or lower container 130 axially shifts relative to the transfer set assembly 200 such that the upper stopper 124 or lower stopper 134 makes contact with upper boot 206 or lower boot 208, respectively. The upper boot 206 or lower boot 208, in turn, is forced against the upper spike 202 or lower spike 204 by the axial translation of the respective container. In the second undesirable displacement position, the upper spike 202 or lower spike 204 each fully penetrate the respective boots 206, 208, and at least partially penetrate the stoppers 124, 134 of respective containers 120, 130. In the second undesirable displacement position of various embodiments, the spikes 202, 204 fully penetrate the respective stoppers 124, 134. In the second undesirable position, the partial or full penetration of the upper 124 or lower 134 stoppers by the upper 202 or lower 204 spikes leads to an increased chance of contamination of the transfer set assembly 200, as well as contamination of the contents of either container 120 or 130.

[0039] In a third undesirable displacement position, the upper container 120 or lower container 130 radially or axially shifts relative to the housing 110, causing a failure of the seals between vials 121, 131 and the interior of housing 110. In the third undesirable displacement position, failed seals could reduce the secure positioning of the upper container 120 and lower container 130 within the housing 110, thereby increasing the likelihood of premature axial translation, and lead to an additional undesirable displacement position.

[0040] Prior to attachment of removable lid 12 to body 14, drug reconstitution assembly 100 is inserted into the interior chamber of the body 14. In doing so, protrusions 16 and 18 and wells 20a to 20c, 22 and 24 mate with different features of the drug reconstitution assembly 100 including and the upper 120 and lower 130 containers held within the drug reconstitution assembly 100.

[0041] Referring now to FIGS. 5 and 6, the protrusions and wells are further illustrated. Wells 20a, 20b and 20c extend outwardly from the body 14 and form a substantially coplanar surface on which the assembly 10 can be supported. Well 20c is shaped to substantially match the outline shape of syringe port plug 140 of the drug reconstitution assembly 100. In the shipping position, syringe port plug 140 faces downward towards the bottom of assembly to mate with well 20c. The syringe port plug 140’s engagement with well 20c inhibits rotational movement of the port within body 14. The syringe port plug 140 also mates with well 20c to provide an additional axial constraint on the housing 100 with respect to the body 14. Orienting the syringe port plug 140 downwardly towards the lower end of assembly 100 prevents the user, upon peeling back removable lid 12, from removing drug reconstitution assembly 100 by the syringe port plug 140, which can increase the likelihood that the plug 140 accidentally detaches from the syringe port increases. Syringe port plug 140 should instead be removed just before the connection of assembly 100 by an external syringe.

[0042] Fig. 5 illustrates that two protrusions 16 extend from package body 14 inwardly into the interior chamber of the body. As illustrated in FIG. 6, protrusions 16 include several geometrical features that are formed to cooperate with mating features of drug reconstitution assembly 100. Specifically, each protrusion 16 includes multiple faces including a tapered face 16a, a lid side face 16b, a body side face 16c, an upper face 16d, and a lower face 16e. FIGS. 1 to 6 make it clear that the two protrusions 16 extend in from the outside of body 14 spaced equally on either side of the longitudinal center of body 14.

[0043] FIG. 2 shows the exploded view of how the drug reconstitution assembly 100 fits within the body 14. When the drug reconstitution assembly 100 is inserted into the body 14, the two protrusions 16, extend through two corresponding apertures 116 of the upper housing portion 112. As illustrated in FIG. 4, protrusion 16 extends through aperture 116 toward the upper container 120. Specifically, body side face 16c of protrusion 16 is configured and arranged to engage with side 116a of the upper housing portion 112 forming aperture 116, the lid side face 16b of protrusion 16 is configured and arranged to engage with side 116b of the upper housing portion 112 forming aperture 116, the upper face 16d is configured and arranged to engage with side 116c of the upper housing portion 112 forming aperture 116, and the lower face 16e is configured and arranged to engage with side 116d of the upper housing portion 112 forming aperture 116.

[0044] The engagement between protrusions 16 and apertures 116 prevents drug reconstitution assembly 100 from translating axially or rotating within body 14. In particular, the lid side face 16b contacts side 116b of the upper housing portion 112 forming aperture 116, and body side face 16c contacts side 116a of the upper housing portion 112 forming aperture 116 to prevent the drug reconstitution assembly 100 from rotating within body 14. Similarly, lower face 16e contacts side 116d of the upper housing portion 112 forming aperture 116, and the upper face 16d contacts side 116c of the upper housing portion 112 forming aperture 116 to prevent the drug reconstitution assembly 100 from translating axially within body 14.

[0045] In various embodiments, the protrusions 16 need not make constant or any contact with the sides 116c, 116d of the aperture 116 while making physical contact with the upper vial 121 of upper container 120. It should be appreciated that the protrusions 16 help to hold upper container 120 secure within the upper housing portion 112 because any axial shift of the upper container 120 is inhibited by the protrusions 16, and any axial shift of the apertures 116 (i.e., the upper housing portion 112) is inhibited by the same protrusions 16. Because the protrusions 16 extend between the apertures 116 and between the neck 122a and rim 126 of the upper vial 121 of upper container 120, the protrusions 16, and therefore the body 14, prevent axial shift of the upper container 120 with respect to the upper housing portion 112.

[0046] Similar to the protrusions 16 discussed above, body 14 also includes two protrusions 18 at its lower end, which extend from body 14 inwardly into the interior chamber of the body. In FIG. 6, one of protrusions 18 is illustrated in greater detail. Like protrusions 16, protrusion 18 includes several geometrical features that are sized and arranged with respect to body 14 to cooperate with mating features of the drug reconstitution assembly 100 when inserted into package 10. Specifically, protrusion 18 includes a tapered face 18a, a lid side face 18b, a body side face 18c, a lower face 18d, and an upper face 18e. FIGS. 1 to 6 make it clear that the two protrusions 18 extend inwardly from body 14 spaced equally on either side of the longitudinal center of body 14.

[0047] FIG. 2 shows that when the drug reconstitution assembly 100 is inserted into the body 14, the two protrusions 18, extend through two corresponding apertures 118 of the lower housing portion 114. As illustrated in FIG. 4, protrusion 18 extends through aperture 118 towards lower container 130. Specifically, the body side face 18c of protrusion 18 is configured to engage with side 118a of the lower housing portion 114 forming aperture 118, the lid side face 18b of protrusion 18 is configured to engage with side 118b of the lower housing portion 114 forming aperture 118, the lower face 18d is configured to engage with side 118c of the lower housing portion 114 forming aperture 118, and the upper face 18e is configured to engage with side 118d the lower housing portion 114 forming aperture 118.

[0048] The engagement between protrusions 18 and apertures 118 prevents drug reconstitution assembly 100 from translating axially or rotating within body 14. In particular, the lid side face 18b contacts side 118b of the lower housing portion 114 forming aperture 118, and body side face 18c contacts side 118a of the lower housing portion 114 forming aperture 118 to prevent the drug reconstitution assembly 100 from rotating within body 14. Similarly, lower face 18d contacts side 118c of the lower housing portion 114 forming aperture 118, and the upper face 18e contacts side 118d of the lower housing portion 114 forming aperture 118 to prevent the drug reconstitution assembly 100 from translating axially within body 14.

[0049] In various embodiments, the protrusions 18 need not make constant or any contact with the sides 118c, 118d of the aperture 118 while making physical contact with the lower vial 131 of lower container 130. It should be appreciated that the protrusions 18 help to hold lower container 130 secure within the lower housing portion 114 because any axial shift of the lower container 130 is inhibited by the protrusions 18, and any axial shift of the apertures 118 (i.e., the lower housing portion 114) is inhibited by the same protrusions 18. Because the protrusions 18 extend between the apertures 118 and between the neck 132a and rim 136 of the lower vial 131 of lower container 130, the protrusions 18, and therefore the body 14, prevent axial shift of the lower container 130 with respect to the lower housing portion 114.

[0050] Protrusions 16 and 18 accordingly work in cooperation to prevent both axial and rotational movement of the housing 110 of the drug reconstitution assembly 100 within the package 10. While two of each protrusion 16 and 18 are illustrated mating respectively with two of each of the apertures 116 and 118, other embodiments include one of each protrusion 16 and 18 mating with one corresponding aperture 116 and 118, or more than two of each protrusion 16,18 mating with more than two corresponding apertures 116, 118. It should also be appreciated that, for reasons discussed in more detail in the ’967 Application, internal mechanisms and frictions within the drug reconstitution assembly 100 serve to secure the upper 120 and lower 130 containers with respect to the housing 110.

[0051] In various embodiments, if the upper 120 or lower 130 containers radially shift about the longitudinal axis of the drug reconstitution assembly 100, various internal seals or components described in more detail in the ’967 Application could be compromised. It should be appreciated that, the protrusions 20c, 16, and 18 cooperate to prevent accidental rotational shift of the upper 120 or lower 130 containers within the housing 110, or any other features of the drug reconstitution assembly 100 within the package 10.

[0052] Referring again to FIGS. 3 to 6, the mating relationship between the body 14 with each of the upper vial 121 of container 120 and the lower vial 131 of lower container 130 is further discussed and illustrated. In addition to the interaction between protrusions 16 with housing 110 apertures 116 and protrusions 18 with housing 110 apertures 118 to prevent movement of housing 110 as described above, protrusions 16 also mate with different features of upper vial 121, while protrusions 18 also mate with different features of lower vial 131 to prevent significant movement of the upper 120 and lower 130 containers. To this end, protrusions 16 and 18 each extend through the respective apertures 116 and 118 to make contact with upper vial 121 and lower vial 131. In various embodiments, axial translation of the upper 120 and 130 containers with respect to the housing 110, and more specifically the upper housing portion 112 and lower housing portion 114 respectively, is inhibited by the protrusions 16 simultaneously engaging with upper vial 121 and apertures 116 and protrusions 18 simultaneously engaging with lower vial 131 and apertures 118.

[0053] As described above, the upper 120 and lower 130 containers are arranged so that the respective shoulders 122b, 132b, necks 122a, 132a, and rims 126, 136 of upper vial 121 and lower vial 131 are aligned with each of the apertures 116, 118 respectively. In the illustrated embodiment, protrusions 16 are configured to contact three different portions of upper vial 121, namely, the shoulder 122b, the neck 122a, and the rim 126. Similarly, the protrusions 18 contact three different portions of lower vial 131, namely, shoulder 132b, the neck 132a, and rim 136. FIG. 2 shows that port plug 140 ensures that apertures 116 and 118 are rotated properly to receive protrusions 16 and 18, respectively.

[0054] Tapered portion 16c of protrusion 16 of body 14 is configured to follow along the contour of and consequently hold the shoulder 122b of the upper vial 121. Likewise, tapered portion 18c of protrusion 18 of body 14 is configured to follow along the contour of and consequently hold shoulder 132b of the lower vial 131. Tapered portions 16a, 18a accordingly also serve to support each of the upper 121 and lower 131 vials so as to prevent significant translational shifting of the respective upper 120 and lower 130 containers within the package 10. To prevent movement of the vials to the undesirable displacement position it should be appreciated that, in various embodiments the tapered portions 16a, 18a need not make constant contact with the contoured shoulders 122b, 132b. Due to the contoured nature of the shoulders 122b, 132b and the corresponding tapered shape of the tapered portions 16a, 16b, the upper 120 and lower 130 containers are urged against shifting relative to the body 14 and the housing 110. The contoured shape of the body also provides a cradling effect that enables a snug fit between the upper 121 and lower 131 vials and the body 14.

[0055] In various embodiments, the lid side face 16b of protrusion 16 of body 14 is arranged to extend towards the neck 122a of the upper vial 121, between rim 126 and shoulder 122b of upper vial 121. Lid side face 16b wedged between rim 126 and shoulder 122b further serves to prevent translational shifting of the upper container 120 within package 10. Similarly, lid side face 18b of protrusion 18 is configured to extend towards neck 132b of lower vial 131 and between the rim 136 and the shoulder 132b of the lower vial 131. Lid side face 18b wedged between rim 136 and the shoulder 132b further serves to prevent translational shifting of the lower container 130 within package 10. To prevent movement of the vials to the undesirable displacement position it should be appreciated that, in various embodiments the lid side faces 16b, 18b need not make constant contact with the rims 126, 136 and shoulders 122b, 132b.

[0056] It should be appreciated that, although the transfer set assembly 200 is not necessarily part of either the upper 112 or lower 114 housings, the transfer set assembly 200 does remain static with respect to the housing due in part to its connection at the syringe port. Therefore, it should be appreciated that for similar principles described above regarding the containers 120,130 and the housing 100, the body 14 and its protrusions 16, 18 also function to prevent axial translation of the upper 120 and lower 130 containers with respect to the transfer set assembly 200.

[0057] Additionally, due to the orientation of the tapers 116a, 118a formed into the body 14, the upper 120 and lower 130 containers are, if anything, urged away from the transfer set assembly 200. As illustrated in FIGS. 4 and 6, the shoulders 122b, 132b of the respective upper 121 and lower 131 vials rest upon the contours 116a, 118a respectively, which are angled such that, absent all other axial obstructions, the upper 120 and lower 130 containers would be unable to shift inward, or toward the transfer set assembly 200, and specifically the upper spike 202 and boot 206 and the lower spike 204 and boot 208 and into the undesirable displacement position. It should be appreciated that the upper 120 and lower 130 containers are inhibited from axial translation with respect to one another for at least the same reasons as why they are inhibited from axial translation with respect to the transfer set assembly 200.

[0058] End portion 22 of body 14 is formed to support and constrain differentfeatures of drug reconstitution assembly 100 when assembled in the package 10. FIG. 4 shows that end portion 22 of the body 14 is configured to constrain the upper container 120 by limiting upward axial movement of upper vial 121. End portion 22 also supports the base portion 122c of upper vial 121. Similarly, end portion 24 of the body 14 is configured to constrain the lower container 130 by limiting downward axial movement of lower vial 131. End portion 24 also supports the base portion 132c of lower vial 131. It should be appreciated that some embodiments include a body 14 that is toleranced such that the end portions 22, 24 make contact or near contact with the respective bottoms of the upper 121 and lower 131 vials, respectively. In various embodiments, the end portions 22, 24 do not make contact with the bottoms of the upper 121 and lower 131 vials respectively.

[0059] It should be appreciated from the above discussion that the geometry and features of formed body 14 interact at multiple contact locations with (i) drug reconstitution assembly 100 to prevent its rotational and translational movement, and (ii) upper 120 and lower 130 containers to prevent their rotational and translational movement into the undesirable displacement position.

It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art.

Claims 1. A medical package assembly (10), the package assembly (10) comprising: a drug reconstitution assembly (100) including: (i) a housing (110), (ii) a container (120, 130) placed at least partially within an interior of the housing (110), and (iii) a spike assembly (200) arranged within the housing so as to be able to spike the container (120, 130); characterized in that the housing forms at least one aperture (116, 118) and the package assembly comprises a body (14) shaped to house the drug reconstitution assembly (100), the body (14) including at least one protrusion (16, 18) extending through the aperture (116, 118) and into the interior of the housing (110), wherein the at least one protrusion (16,18) is positioned and arranged to prevent movement of the container (120, 130) toward the spike assembly (200) prior to the container (120, 130) reaching an undesirable displacement relative to the spike assembly (200). 2. The medical package assembly (10) of Claim 1, which includes a lid (12) attached to the body (14) and configured to sealingly enclose the drug reconstitution assembly (100) within the body (14). 3. The medical package assembly (10) of Claim 2, wherein the lid (12) is attached to the body (14) with heat-activated adhesive. 4. The medical package assembly (10) of Claim 2, wherein the at least one protrusion (16, 18) is configured to prevent axial translation of the container (120, 130) relative to the housing (110). 5. The medical package assembly (10) of Claim 1, wherein the at least one protrusion (16, 18) further prevents rotation of the drug reconstitution assembly (100) within the body (14). 6. The medical package assembly (10) of Claim 1, wherein the body (14) is structured with at least one flat surface so as to prevent rolling of the body (14). 7. The medical package assembly (10) of Claim 1, wherein the drug reconstitution assembly (100) includes a syringe port plug (140) and the body includes a cavity (20c) shaped to mate with the syringe port plug (140) of the drug reconstitution assembly (100). 8. The medical package assembly (10) of Claim 1, wherein the container (120, 130) is a first container (120), and which includes a second container (130) placed at least partially within the housing (110) of the drug reconstitution assembly (100), the housing (110) forming at least one second aperture (118) wherein the at least one protrusion (16, 18) is a first protrusion (16) and which includes a second protrusion (18), the second protrusion (18) positioned and arranged to extend through the second aperture (118) and into the interior of the housing (110) and prevent movement of the second container (130) toward the spike assembly (200) prior to the second container (130) reaching an undesirable displacement relative to the spike assembly (200). 9. The medical package assembly (10) of Claim 1, wherein the container (120, 130) is a first vial (120) including a neck (122a) and a shoulder (122b), the first vial (120) arranged relative to the housing (110) to align at least a portion of the neck (122a) of the first vial (120) with the at least one aperture (116), the at least one protrusion (16) configured to extend toward the neck (122a) and engage the shoulder (122b) prior to the first vial (120) reaching an undesirable displacement relative to the spike assembly (200). 10. The medical package assembly (10) of Claim 9, further including a second container (130) placed at least partially within the housing (110) of the drug reconstitution assembly (100) and the second container (130) is a vial including a neck (132a) and a shoulder (132b), wherein the at least one aperture (116,118) is at least one first aperture and the housing (110) forming at least one second aperture (118a), the second container (130) arranged relative to the housing (110) to align at least a portion of the neck (132a) of the second container (130) with the at least one second aperture (118) wherein the at least one protrusion (16,18) is a first protrusion (16) and the body (14) forming a second protrusion (18), the second protrusion (18) positioned and arranged to extend through the second aperture (118) and into the interior of the housing toward the neck (132a) of the second container (130) and engage the shoulder (132b) of the second container ( 130) prior to the second container (130) reaching an undesirable displacement relative to the spike assembly (200). 11. A drug delivery product (10) comprising: a drug reconstitution assembly (100) including a housing (110) and first and second containers (120, 130) placed within the housing (110); characterized by a package including a body (14) shaped to house the drug reconstitution assembly (100), at least one first protrusion (16, 18) extending from the body (14), the at least one first protrusion (16, 18) positioned and arranged to engage the housing (110) and the first container (120, 130) to inhibit axial translation of the first container (120, 130) relative to the housing (110), and the body (14) including a second protrusion (18) positioned and arranged to engage with the housing (110) to inhibit axial translation of the second container (130) relative to the housing (14). 12. The drug delivery product (10) of Claim 11, wherein the first protrusion (16) engages the housing (110) at a first location adjacent the first container (120) and the second protrusion (18) engages the housing (110) at a second location adjacent the second container (130). 13. The drug delivery product (10) of Claim 11, wherein the first and second engagements include the first and second protrusions (16, 18) extending through first and second apertures (116, 118), respectively, of the housing (110). 14. The drug delivery product (10) of Claim 13, wherein at least one of: (i) the first aperture (116) is one of a plurality of first apertures (116) spaced radially about the housing (110) or (ii) the second aperture (118) is one of a plurality of second apertures (118) spaced radially about the housing (110). 15. The drug delivery product (10) of Claim 13, wherein the first and second protrusions (16, 18) extending through the first and second apertures (116, 118) further inhibit rotational movement of the housing (110) relative to the body (14). 16. The drug delivery product (10) of Claim 11, wherein the first and second containers (120, 130) are accessed by a transfer set assem bly (130), the transfer set assembly (130) including a port accessible by a user, the body (14) including a well (20c) positioned and arranged to engage the port, or a plug (140) plugging the port, to inhibit axial movement of the housing (110). 17. The drug delivery product (10) of Claim 11, wherein the engagement of the drug reconstitution assembly (100) by the at least one protrusion (16, 18) also inhibits rotational movement of the housing (110) relative to the body (14). 18. The drug delivery product (10) of Claim 11, wherein the engagement of the drug reconstitution assembly (100) by the at least one protrusion (16, 18) also inhibits axial movement of the housing (110) relative to the body (14). 19. A method of packaging a drug reconstitution assembly (100), comprising: providing a package with a removable lid (12) and a body (14) configured to house the drug reconstitution assembly (100), including at least one protrusion (16,18) extending from the body (14); providing the drug reconstitution assembly (100) with a housing (110) having at least one aperture (116,118), and a container (120,130) placed at least partially within the housing (110), wherein a neck portion (122a, 132a) of the container (120, 130) aligns with at least one of the apertures (116, 118) of the housing (110); assembling the drug reconstitution assembly (100) within the body (14) of the package, such that the at least one protrusion (16, 18) of the body (14) extends through at least one of the apertures (116,118) of the housing, wherein an orientation of the drug reconstitution assembly (100) within the package is limited to a predetermined number of orientations; and sealing the drug reconstitution assembly (100) within the body (14) of the package with the removable lid (12).

Patentansprüche 1. Medizinische Verpackungsanordnung (10), wobei die Verpackungsanordnung (10) Folgendes umfasst: eine Arzneimittel-Rekonstitutionsanordnung (100), die Folgendes beinhaltet: (i) ein Gehäuse (110), (ii) einen Behälter(120,130),derzumindest teilweise im Inneren des Gehäuses (110) angeordnet ist, und (iii) eine Dornanordnung (200), die derart in dem Gehäuse angeordnet ist, dass sie in der Lage ist, den Behälter (120, 130) zu durchstechen, dadurch gekennzeichnet, dass das Gehäuse mindestens eine Öffnung (116, 118) bildet und die Verpackungsanordnung einen Hauptteil (14) umfasst, der dafür geformt ist, die Arzneimittel-Rekonstitutionsanordnung (100) zu beherbergen, wobei der Hauptteil (14) mindestens einen Vorsprung (16, 18) beinhaltet, der sich durch die Öffnung (116, 118) und in das Innere des Gehäuses (110) erstreckt, wobei der mindestens eine Vorsprung (16, 18) dafür positioniert und angeordnet ist, die Bewegung des Behälters (120, 130) hin zur Dornanordnung (200) zu verhindern, bevor der Behälter (120,130) eine unerwünschte Verschiebung im Verhältnis zur Dornanordnung (200) erreicht. 2. Medizinische Verpackungsanordnung (10) nach Anspruch 1, die eine Abdeckung (12) beinhaltet, die am Hauptteil (14) angebracht und dafür gestaltet ist, die Arzneimittel-Rekonstitutionsanordnung (100) versiegelt im Hauptteil (14) einzuschließen. 3. Medizinische Verpackungsanordnung (10) nach An-

Spruch 2, wobei die Abdeckung (12) mit einem Schmelzklebstoff am Hauptteil (14) angebracht ist. 4. MedizinischeVerpackungsanordnung (10) nach Anspruch 2, wobei der mindestens eine Vorsprung (16, 18) dafür gestaltet ist, eine axiale Verlagerung des Behälters (120, 130) im Verhältnis zum Gehäuse (110) zu verhindern. 5. MedizinischeVerpackungsanordnung (10) nach Anspruch 1, wobei der mindestens eine Vorsprung (16, 18) ferner das Drehen der Arzneimittel-Rekonstitutionsanordnung (100) im Hauptteil (14) verhindert. 6. MedizinischeVerpackungsanordnung (10) nach Anspruch 1, wobei der Hauptteil (14) mit mindestens einer ebenen Fläche strukturiert ist, so dass ein Rollen des Hauptteils (14) verhindert wird. 7. MedizinischeVerpackungsanordnung (10) nach Anspruch 1, wobei die Arzneimittel-Rekonstitutionsanordnung (100) einen Spritzenanschlussstöpsel (140) und der Hauptteil einen Hohlraum (20c) beinhaltet, der derart geformt ist, dass er mit dem Spritzenanschlussstöpsel (140) der Arzneimittel-Rekonstitutionsanordnung (100) übereinstimmt. 8. MedizinischeVerpackungsanordnung (10) nach Anspruch 1, wobei der Behälter (120, 130) ein erster Behälter (120) ist, und welche einen zweiten Behälter (130) beinhaltet, der zumindest teilweise im Gehäuse (110) der Arzneimittel-Rekonstitutionsanordnung (1 00) angeordnet ist, wobei das Gehäuse (110) mindestens eine zweite Öffnung (118) bildet, wobei der mindestens eine Vorsprung (16, 18) ein erster Vorsprung (16) ist, wobei die Verpackung einen zweiten Vorsprung (18) beinhaltet, wobei der zweite Vorsprung (18) dafür positioniert und angeordnet ist, sich durch die zweite Öffnung (118) und in das Innere das Gehäuses (110) zu erstrecken und eine Bewegung des zweiten Behälters (130) hin zur Dornanordnung (200) zu verhindern, bevor der zweite Behälter (130) eine unerwünschte Verschiebung im Verhältnis zur Dornanordnung (200) erreicht. 9. MedizinischeVerpackungsanordnung (10) nach Anspruch 1, wobei der Behälter (120, 130) eine erste Ampulle (120) ist, die einen Hals (122a) und einen Ansatz (122b) beinhaltet, wobei die erste Ampulle (120) im Verhältnis zum Gehäuse (110) derart angeordnet ist, dass mindestens ein Teil des Halses (122a) der ersten Ampulle (120) an der mindestens einen Öffnung (116) ausgerichtet ist, wobei der mindestens eine Vorsprung (16) dafür gestaltet ist, sich hin zum Hals (122a) zu erstrecken und mit dem Ansatz (122b) in Eingriff zu gelangen, bevor die erste Ampulle (120) eine unerwünschte Verschiebung im Verhältnis zur Dornanordnung (200) erreicht. 10. Medizinische Verpackungsanordnung (10) nach Anspruch 9, ferner einen zweiten Behälter (130) beinhaltend, der zumindest teilweise im Gehäuse (110) der Arzneimittel-Rekonstitutionsanordnung (100) angeordnet ist, wobei der zweite Behälter (130) eine Ampulle ist, die einen Hals (132a) und einen Ansatz (132b) beinhaltet, wobei die mindestens eine Öffnung (116, 118) mindestens eine erste Öffnung ist und das Gehäuse (110) mindestens eine zweite Öffnung (11 8a) bildet, wobei der zweite Behälter (130) im Verhältnis zum Gehäuse (110) derart angeordnet ist, dass mindestens ein Teil des Halses (132a) des zweiten Behälters (130) an der mindestens einen zweiten Öffnung (118) ausgerichtet ist, wobei der mindestens eine Vorsprung (16, 18) ein erster Vorsprung (16) ist und der Hauptteil (14) einen zweiten Vorsprung (18) bildet, wobei der zweite Vorsprung (18) dafür positioniert und angeordnet ist, sich durch die zweite Öffnung (118) und in das Innere des Gehäuses hin zum Hals (132a) des zweiten Behälters (130) zu erstrecken und mit dem Ansatz (132b) des zweiten Behälters (130) in Eingriff zu gelangen, bevor der zweite Behälter (130) eine unerwünschte Verschiebung im Verhältnis zur Dornanordnung (200) erreicht. 11. Arzneimittel-Abgabeprodukt (10), Folgendes umfassend: eine Arzneimittel-Rekonstitutionsanordnung (100), die ein Gehäuse (110) und einen ersten und einen zweiten Behälter (120, 130) beinhaltet, die im Gehäuse (110) angeordnet sind, gekennzeichnet durch eine Verpackung, die einen Hauptteil (14) beinhaltet, der dafür geformt ist, die Arzneimittel-Rekonstitutionsanordnung (1 00) zu beherbergen, wobei sich mindestens ein erster Vorsprung (16,18) vom Hauptteil (14) aus erstreckt, wobei der mindestens eine erste Vorsprung (16, 18) dafür positioniert und angeordnet ist, mitdem Gehäuse (110) und dem ersten Behälter (120, 130) in Eingriff zu gelangen, um eine axiale Verlagerung des ersten Behälters (120, 130) im Verhältnis zum Gehäuse (110) zu unterbinden, und wobei der Hauptteil (14) einen zweiten Vorsprung (18) beinhaltet, der dafür positioniert und angeordnet ist, mit dem Gehäuse (110) in Eingriff zu gelangen, um eine axiale Verlagerung des zweiten Behälters (130) im Verhältnis zum Gehäuse (14) zu unterbinden. 12. Arzneimittel-Abgabeprodukt (10) nach Anspruch 11, wobei der erste Vorsprung (16) an einer ersten Stelle mit dem Gehäuse (110) in Eingriff gelangt, die an den ersten Behälter (120) angrenzt, und der zweite Vorsprung (18) an einer zweiten Stelle mitdem Gehäuse (110) in Eingriff gelangt, die an den zweiten

Behälter (130) angrenzt. 13. Arzneimittel-Abgabeprodukt (10) nach Anspruch 11, wobei die erste und die zweite Ineingriffnahme beinhalten, dass sich der erste und der zweite Vorsprung (16,18) durch die erste beziehungsweise die zweite Öffnung (116, 118) des Gehäuses (110) erstrecken. 14. Arzneimittel-Abgabeprodukt (10) nach Anspruch 13, wobei (i) die erste Öffnung (116) eine von mehreren ersten Öffnungen (116) ist, die radial um das Gehäuse (110) herum beabstandet sind, und/oder (ii) die zweite Öffnung (118) eine von mehreren zweiten Öffnungen (118) ist, die radial um das Gehäuse (110) herum beabstandet sind. 15. Arzneimittel-Abgabeprodukt (10) nach Anspruch 13, wobei der erste und der zweite Vorsprung (16, 18), die sich durch die erste und die zweite Öffnung (116, 118) erstrecken, ferner einer Drehbewegung des Gehäuses (110) im Verhältnis zum Hauptteil (14) unterbinden. 16. Arzneimittel-Abgabeprodukt (10) nach Anspruch 11, wobei der erste und der zweite Behälter (120, 130) für eine Übertragungssatzanordnung (130) zugänglich sind, wobei die Übertragungssatzanordnung (130) einen Anschluss beinhaltet, der für einen Benutzer zugänglich ist, wobei der Hauptteil (14) eine Wanne (20c) beinhaltet, die dafür positioniert und angeordnet ist, mit dem Anschluss odereinem Stöpsel (140), der den Anschluss verstöpselt, in Eingriff zu gelangen, um eine axiale Bewegung des Gehäuses (110) zu unterbinden. 17. Arzneimittel-Abgabeprodukt(IO) nach Anspruch 11, wobei die Ineingriffnahme der Arzneimittel-Rekonstitutionsanordnung (100) durch den mindestens einen Vorsprung (16, 18) außerdem die Drehbewegung des Gehäuses (110) im Verhältnis zum Hauptteil (14) unterbindet. 18. Arzneimittel-Abgabeprodukt (10) nach Anspruch 11, wobei die Ineingriffnahme der Arzneimittel-Rekonstitutionsanordnung (100) durch den mindestens einen Vorsprung (16,18) außerdem die axiale Bewegung des Gehäuses (110) im Verhältnis zum Hauptteil (14) unterbindet. 19. Verfahren zum Verpacken einer Arzneimittel-Rekonstitutionsanordnung (100), Folgendes umfassend:

Bereitstellen einer Verpackung mit einer abnehmbaren Abdeckung (12) und einem Hauptteil (14), der dafür gestaltet ist, die Arzneimittel-Rekonstitutionsanordnung (100) zu beherber gen und mindestens einen Vorsprung (16, 18) beinhaltet, der sich vom Hauptteil (14) aus erstreckt,

Bereitstellen eines Gehäuses (110) für die Arzneimittel-Rekonstitutionsanordnung (100), das mindestens eine Öffnung (116, 118) und einen Behälter (120,130) aufweist, der zumindest teilweise im Gehäuse (110) angeordnet ist, wobei ein Halsabschnitt (122a, 132a) des Behälters (120, 130) an mindestens einer der Öffnungen (116,118) des Gehäuses (110) ausgerichtet ist, Anordnen der Arzneimittel-Rekonstitutionsanordnung (100) im Hauptteil (14) der Verpackung derart, dass sich der mindestens eine Vorsprung (16, 18) des Hauptteils (14) durch mindestens eine der Öffnungen (116,118) des Gehäuses erstreckt, wobei eine Ausrichtung der Arzneimittel-Rekonstitutionsanordnung (100) in der Verpackung auf eine festgelegte Anzahl von Ausrichtungen begrenzt ist, und Abdichten der Arzneimittel-Rekonstitutionsanordnung (100) im Hauptteil (14) der Verpackung mit der abnehmbaren Abdeckung (12).

Revendications 1. Ensemble emballage médical (10), l’ensemble emballage (10) comprenant : un ensemble reconstitution de médicament (100) incluant : (i) un logement (110), (ii) un contenant (120, 130) placé au moins partiellement à l’intérieur du logement (110), et (iii) un ensemble transpercement (200) agencé au sein du logement defaçon à pouvoir transpercer le contenant (120, 130) ; caractérisé en ce que le logement forme au moins une ouverture (116, 118) et l’ensemble emballage comprend un corps (14) conformé pour loger l’ensemble reconstitution de médicament (100), le corps (14) incluant au moins une protrusion (16, 18) s’étendant à travers l’ouverture (116, 118) et dans l’intérieur du logement (110), dans lequel la au moins une protrusion (16,18) est positionnée et agencée pour empêcher un mouvement du contenant (120, 130) vers l’ensemble transpercement (200) avant que le contenant (120,130) n’atteigne un déplacement non souhaitable par rapport à l’ensemble transpercement (200). 2. Ensemble emballage médical (10) selon la revendication 1, qui inclut un couvercle (12) attaché au corps (14) et configuré pour enserrer de manière étanche l’ensemble reconstitution de médicament (100) au sein du corps (14). 3. Ensemble emballage médical (10) selon la revendication 2, dans lequel le couvercle (12) est attaché au corps (14) via un adhésif activé à la chaleur. 4. Ensemble emballage médical (10) selon la revendication 2, dans lequel la au moins une protrusion (16, 18) est configurée pour empêcher une translation axiale du contenant (120, 130) par rapport au logement (110). 5. Ensemble emballage médical (10) selon la revendication 1, dans lequel la au moins une protrusion (16, 18) empêche en outre une rotation de l’ensemble reconstitution de médicament (100) au sein du corps (14). 6. Ensemble emballage médical (10) selon la revendication 1, dans lequel le corps (14) est structuré avec au moins une surface plate de façon à empêcher le roulement du corps (14). 7. Ensemble emballage médical (10) selon la revendication 1, dans lequel l’ensemble reconstitution de médicament (100) inclut un bouchon d’orifice de seringue (140) et le corps inclut une cavité (20c) conformée pour s’accoupler avec le bouchon d’orifice de seringue (140) de l’ensemble reconstitution de médicament (100). 8. Ensemble emballage médical (10) selon la revendication 1, dans lequel le contenant (120, 130) est un premier contenant (120), et qui inclut un second contenant (130) placé au moins partiellement au sein du logement (110) de l’ensemble reconstitution de médicament (100), le logement (110) formant au moins une seconde ouverture (118), la au moins une protrusion (16, 18) étant une première protrusion (16) et qui inclut une seconde protrusion (18), la seconde protrusion (18) étant positionnée et agencée pour s’étendre à travers la seconde ouverture (118) et dans l’intérieur du logement (110) et empêcher un mouvement du second contenant (130) vers l’ensemble transpercement (200) avant que le second contenant (130) n’atteigne un déplacement non souhaitable par rapport à l’ensemble transpercement (200). 9. Ensemble emballage médical (10) selon la revendication 1, dans lequel le contenant (120, 130) est un premier flacon (120) incluant un goulot (122a) et un épaulement (122b), le premier flacon (120) étant agencé par rapport au logement (110) pour aligner au moins une partie du goulot (122a) du premierfla-con (120) avec la au moins une ouverture (116), la au moins une protrusion (16) étant configurée pour s’étendre vers le goulot (122a) et enclencher l’épau-lement(122b) avant que le premierflacon (120) n’atteigne un déplacement non souhaitable par rapport à l’ensemble transpercement (200). 10. Ensemble emballage médical (10) selon la revendication 9, incluant en outre un second contenant (130) placé au moins partiellement au sein du logement (110) de l’ensemble reconstitution de médicament (100), et le second contenant (130) est un flacon incluant un goulot (132a) et un épaulement (132b), la au moins une ouverture (116,118), étant au moins une première ouverture et le logement (110) formant au moins une seconde ouverture (118a), le second contenant (130) étant agencé par rapport au logement (110) pour aligner au moins une partie du goulot (132a) du second contenant (130) avec la au moins une seconde ouverture (118), la au moins une protrusion (16, 18) étant une première protrusion (16) et le corps (14) formant une seconde protrusion (18), la seconde protrusion (18) étant positionnée et agencée pour s’étendre à travers la seconde ouverture (118) et dans l’intérieur du logement vers le goulot (132a) du second contenant (130) et enclencher l’épaulement (132b) du second contenant (130) avant que le second contenant (130) n’atteigne un déplacement non souhaitable par rapport à l’ensemble transpercement (200). 11. Produit de délivrance de médicament (10) comprenant : un ensemble reconstitution de médicament (100) incluant un logement (110), et des premier et second contenants (120,130) placés au sein du logement (110) ; caractérisé par un emballage incluant un corps (14) conformé pour loger l’ensemble reconstitution de médicament (100), au moins une première protrusion (16, 18) s’étendant depuis le corps (14), la au moins une première protrusion (16,18) est positionnée et agencée pour enclencher le logement (110) et le premier contenant (120,130) pour inhiber une translation axiale du premier contenant (120, 130) par rapport au logement (110), et le corps (14) incluant une seconde protrusion (18) positionnée et agencée pour s’enclencher avec le logement (110) pour inhiber une translation axiale du second contenant (130) par rapport au logement (14). 12. Produit de délivrance de médicament (10) selon la revendication 11, dans lequel la première protrusion (16) enclenche le logement (110) à un premier emplacement adjacent au premier contenant (120) et la seconde protrusion (18) enclenche le logement (110) à un second emplacement adjacent au second contenant (130). 13. Produit de délivrance de médicament (10) selon la revendication 11, dans lequel les premier et second enclenchements incluent les première et seconde protrusions (16,18) s’étendant à travers des première et seconde ouvertures (116, 118), respectivement, du logement (110). 14. Produit de délivrance de médicament (10) selon la revendication 13, dans lequel au moins l’une parmi : (i) la première ouverture (116) est l’une d’une pluralité de premières ouvertures (116) espacées radia-lement autour du logement (110) ou (ii) la seconde ouverture (118) est l’une d’une pluralité de secondes ouvertures (118) espacées radialement autour du logement (110). 15. Produit de délivrance de médicament (10) selon la revendication 13, dans lequel les première et seconde protrusions (16, 18) s’étendant à travers les première et seconde ouvertures (116,118) inhibent en outre un mouvement de rotation du logement (110) par rapport au corps (14). 16. Produit de délivrance de médicament (10) selon la revendication 11, dans lequel on accède aux premier et second contenants (120, 130) par un ensemble jeu de transfert (130), l’ensemble jeu de transfert (130) incluant un orifice accessible par un utilisateur, le corps (14) incluant un puits (20c) positionné et agencé pour enclencher l’orifice, ou un bouchon (140) bouchant l’orifice, pour inhiber un mouvement axial du logement (110). 17. Produit de délivrance de médicament (10) selon la revendication 11, dans lequel l’enclenchement de l’ensemble reconstitution de médicament (100) par la au moins une protrusion (16,18) inhibe également un mouvement de rotation du logement (110) par rapport au corps (14). 18. Produit de délivrance de médicament (10) selon la revendication 11, dans lequel l’enclenchement de l’ensemble reconstitution de médicament (100) par au moins une protrusion (16, 18) inhibe également un mouvement axial du logement (110) par rapport au corps (14). 19. Procédé d’emballage d’un ensemble reconstitution de médicament (100) comprenant : le fait de doter un emballage d’un couvercle amovible (12) et d’un corps (14) configuré pour loger l’ensemble reconstitution de médicament (100), incluant au moins une protrusion (16,18) s’étendant à partir du corps (14) ; le fait de doter l’ensemble reconstitution de mé dicament (100) d’un logement (110) ayant au moins une ouverture (116, 118), et d’un contenant (120, 130) placé au moins partiellement au sein du logement (110), une partie de goulot (122a, 132a) du contenant (120,130) s’alignant avec au moins l’une des ouvertures (116, 118) du logement (110) ; l’assemblage de l’ensemble reconstitution de médicament (100) au sein du corps (14) de l’emballage, de telle sorte qu’au moins une protrusion (16,18) du corps (14) s’étende à travers au moins l’une des ouvertures (116, 118) du logement, une orientation de l’ensemble reconstitution de médicament (100) au sein de l’emballage étant limitée à un nombre prédéterminé d’orientations ; et l’obturation de l’ensemble reconstitution de médicament (100) au sein du corps (14) de l’emballage avec le couvercle amovible (12).

Claims (6)

GSOlÂTOl ^ êECTSia PRE-ACTIVATED ACTIVATION TREATMENT iiilıilÂir✠^ j, st st st st st st st st st st st 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 tartalma tartalma tartalma tartalma tartalma tartalma:::::::::::::::::::: egy egy egy egy egy egy egy egy egy egy::: | | | | | | |. Pl cgj container (120, ISO), which is at least partially inside the housing (110) and (!!!) is a drumstick (200), which is: in the housing edge: to view the container (1.20, tiO) to filter through the &#ai character "? " that the housing forms at least one arrow (11.6, 118), and the packing unit has a flap (14) configured or shaped to receive a drug-related siludic epithelium (1.00), and the body comprises at least one protrusion or protrusion (16, 18) extending through the aperture (116, 118) extending into the interior of the housing (11.0), mimicking at least one Μηναίο part (16, 18) is positioned and arranged to prevent the container (120, 130) from moving towards the mandrel unit before the container (120, 130) is positioned relative to the mandrel assembly (200). to the desired position 2, the medical package according to claim L! unit (10b comprising a cover (12) of dl ^ ^ È ^ tatÂ: and formed in such a manner that the drug reconstitution unit (100 µmt) is incorporated into the body f 14); The packaging unit (10) according to claim 1, wherein the lid (12) is bonded to the body (14) by heat-activated adhesive agar 4. The medical packaging unit (10) of claim 2, wherein said at least a protruding portion (1§, IS) is engaged to prevent the container (120, 130) from being housed (ID I) by the axially displaced axial displacement, A medical packaging unit (10) as claimed in claim 1, wherein the at least one protruding portion (16, IS) further prevents rotations within the body (14) of the reciprocating assembly. The medical packaging unit (10) of claim 1, wherein the at least one flat surface of the body (14) is structured so that the gord seat of the body (14) is blocked, The medical packaging unit (10) according to claim 1, wherein the hoGfazer-reconstituted unit has a plunger (140) sealing the reticulation of the needle, and the body has a cavity (120c) which is formed as follows: or formatted, that feskenáő ^ Mdmlényilás is connected to, and fits with, the zebra: the movable (140). The medical packaging unit according to claim 1u, wherein the container (120, 130) is a first container (120), and the unit comprises a second container (130) which is at least partially in the form of a container. # | pnsti'tübl # s is located inside the housing (110) of the unit (100) and the housing (110) forms at least one second opening (1 IS)! i that at least one protruding portion (16, 18) is a first protruding portion (16), the packaging unit comprising a second protruding portion (18), and this second molding portion (18) is positioned and arranged to pass through touch or ?, the second nylis (1! 8 | and penetrate the inside of the housing (110) and prevent the second container (130) from moving into the mandrel unit (200) before the second container is overweighted: undesirable displacement 91 The medical package according to claim 1 is a container (120, a first ampoule (120) having a neck (122a! and a shoulder (122b) and a first ampoule (1: 20) to the housing: (1:10): relative to the manner in which at least a portion of the neck (122a) of the first ampoule (120) is aligned with the at least one opening (116), with at least one protruding portion (116). 16) in such a manner that the neck (122a) is up * Iietye extends into the neck and a completeness, and Vail (122b) is connected prior to the first vial (121 | the medical packaging unit (10) according to claim 9, further comprising a second container (130), at least partially in the form of the reconstitution of the nut: (ii) on the spigot unit (200) (110) is located inside and the second container (ISO) is an ampoule having a neck (132a) and a shoulder (132b), with at least one opening (116, 118) being at least one front opening and a housing. (.110) at least one second arrow (1 Sa) is formed and the second container (ISO) is arranged relative to the housing (110) such that at least a portion of the neck (132a) of the second container (130) is aligned the at least one second opening (118), wherein the latch (16, 181 is a first protruding portion (16) and the body (14) is a second protruding portion (18); is positioned and arranged to extend the second k (118) and projecting into the interior of the housing in the direction of the neck (132a) of the second container (130), and the second container (13hoz) is attached to the sleeve (132b) before the second container (130) a. tuskemgységhcz (210): would move to an unwanted position. An opo-map (10), comprising: a pharmaceutical reconstitution unit (100) having a housing p ΙΟΙ and a housing (110 and 130 in the housing 110). characterized by an oho package having a body body (14) "configured or shaped to receive the drug reconstructive unit (100); and at least one first protruding portion (16, 1.8) extending from the body (14), the at least one first protruding portion (1.6, 18) is positioned and arranged to engage with the housing (110) and the first container (120, 130) for its first container | 130) inhibiting the movement of an azal relative to the housing (110); and that the body (14) includes a second protruding portion (18) positioned and arranged in such a manner that it can be self-contained with the housing (110) so that its barrier against the second container (Î3Û) relative to the body (| 4). axili · e! m ozgisit, 1 2. The inventive unit (10) of claim 11, wherein the first protruding portion (16) is connected to the housing (110) at a first location adjacent to the first container (120) , and the second protruding portion (1.8) a. a housing (110) is connected to a second location adjacent to the second container (130). The eyelid herititis unit (100) of claim 11, wherein the first and second ejection attachments include the first and second protruding portions (16, 18) passing through the first and second openings of the housing (11.0). (116, 118) .. 14, The pharmaceutical reconstitution unit (100) of claim 13, wherein (i) a first opening (116) is provided by the first opening (116) which is radially spaced away from the housing: 110) cough; and / or (i) a plurality of second father ff 18}, which is radially remotely located at the housing (1.10}. 15 ". A pharmaceutical reconstitution unit (100) according to claim 13, wherein the first and second protruding portions extending through the edges and the second opening (116, 118), furthermore, inhibit the rotational movement of the housing relative to the body fi4} 16. Ä The pharmaceutical assembly unit according to claim 11 (100), wherein the first and second reservoirs (120, 130) are accessible to a stock placement unit (ISO), said stock placement unit (130) having a user-accessible opening, and body {14} includes a turret (20c), which means is positioned and arranged to engage the aperture or plug {140) which connects the aperture to inhibit the movement of the housing (110} to the apo. a member of the elongated unit, wherein the interconnection of the drug-institutional unit {100}, furthermore, prevents the rotating moiety of the mice (110) from rotating at least one part (16, 18). relative to body {14}, 18. Ä a $ $ zir "reconstituted unit {300) according to claim 11, the drug reconstitution unit (100) is terminated by means of the at least one protruding part (shoot, 18}). (110} azile movement to the body {14} fcva. 1í, l e l e e e e e rock on on on on on on on on on on on on on amely amely amely amely amely amely amely amely amely amely amely amely amely amely amely amely amely amely amely eljárás eljárás eljárás eljárás eljárás eljárás eljárás eljárás eljárás eljárás eljárás é 14), the latter being adapted to receive the drug reconstitution, and the package comprising at least one protruding portion (16, 18) extending from the body (14); a housing wall (loO) having at least one opening (116, III) and at least one container (120, 1.30) located at least partially inside the housing (110), besides a neck portion of the container (t0, 130) 122a, 132a) at the leading edge of the housing (110) with at least one arrow (116, 18); (100) within the body (14) of the package, such that it extends through at least one protruding portion (16, 18) of the body (14), whistling at an opening in the body of the body: ($ 116.11) ), besides, the orientation of the filamentous crystal lattice integrity (100) within the essay is limited to a predetermined number of orientations; and sealing the unit (100) in a sealed or airtight manner in the package body (14) with the removable cover (12),